Skip to main content

Advertisement

SpringerLink
Log in

Pediatric Inpatient Dermatology: New Insights on Severe Eruptions and Cutaneous Adverse Reactions

  • Hospital- based Dermatology (D Kroshinsky, Section Editor)
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This manuscript reviews important advances in our understanding of severe eruptions and cutaneous adverse reactions in children.

Recent Findings

The latest research provides significant insights regarding severe cutaneous eruptions including coxsackievirus eruptions, mycoplasma-induced rash and mucositis, urticaria multiforme, erythema multiforme, and severe cutaneous adverse reactions. Recent literature expands our understanding of the incidence and cost, pathophysiology, and management considerations for pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Summary

Pediatric inpatient cutaneous eruptions, from infectious and inflammatory to adverse reactions are very burdensome diseases. It is important to recognize salient features to initiate appropriate workup and management, particularly for patients with severe cutaneous adverse reactions for which early recognition of complications of disease and consultation with colleagues may minimize sequelae.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hubiche T, Schuffenecker I, Boralevi F, Léauté-Labrèze C, Bornebusch L, Chiaverini C, et al. Dermatological spectrum of hand, foot and mouth disease from classical to generalized exanthema. Pediatr Infect Dis J. 2014;33(4):e92–8.

    Article  Google Scholar 

  2. •• Mathes EF, Oza V, Frieden IJ, Cordoro KM, Yagi S, Howard R, et al. “Eczema coxsackium” and unusual cutaneous findings in an enterovirus outbreak. Pediatrics. 2013;132(1):e149–57 A retrospective case series describing atypical presentations of HFMD associated with a North American CVA6 outbreak.

    Article  Google Scholar 

  3. Nassef C, Ziemer C, Morrell DS. Hand-foot-and-mouth disease: a new look at a classic viral rash. Curr Opin Pediatr. 2015;27(4):486–91.

    Article  CAS  Google Scholar 

  4. Neri I, Dondi A, Wollenberg A, Ricci L, Ricci G, Piccirilli G, et al. Atypical forms of hand, foot, and mouth disease: a prospective study of 47 Italian children. Pediatr Dermatol. 2016;33(4):429–37.

    Article  Google Scholar 

  5. Apalla Z, Sotiriou E, Pikou O, Lefaki I, Lallas A, Lazaridou E, et al. Onychomadesis after hand-foot-and-mouth disease outbreak in northern Greece: case series and brief review of the literature. Int J Dermatol. 2015;54(9):1039–44.

    Article  Google Scholar 

  6. Böer-Auer A, Metze D. Histopathology of hand-foot-mouth disease in adults and criteria for differentiation from erythema multiforme. Am J Dermatopathol. 2018;11.

  7. •• Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72(2):239–45 Classification of MIRM as a clinical entity distinct from other mucocutaneous eruptions, with diagnostic and morphological criteria described.

    Article  Google Scholar 

  8. Santos RP, Silva M, Vieira AP, Brito C. Mycoplasma pneumoniae-induced rash and mucositis: a recently described entity. BMJ Case Rep. 2017;22:2017.

    Google Scholar 

  9. Curtiss P, Melnick L, Sicco KL, Liebman TN. Mycoplasma pneumoniae, more than a lung disease. Dermatol Online J. 2018;24(6).

  10. Norton SA. Diagnosing Mycoplasma pneumoniae-induced rash and mucositis (MIRM) in the emergency room. J Am Acad Dermatol. 2015;73(2):e67.

    Article  Google Scholar 

  11. Mayor-Ibarguren A, Feito-Rodriguez M, González-Ramos J, Del Rosal-Rabes T, González-Sainz FJ, Sánchez-Orta A, et al. Mucositis secondary to Chlamydia pneumoniae infection: expanding the Mycoplasma pneumoniae-induced rash and mucositis concept. Pediatr Dermatol. 2017;34(4):465–72.

    Article  Google Scholar 

  12. Samorano LP, Fernandez VV, Valente NYS, Arnone M, Nico MMS, Rivitti-Machado MCM, et al. Urticaria multiforme: two cases with histopathological findings. Allergol Int Off J Jpn Soc Allergol. 2017;66(1):154–5.

    Article  Google Scholar 

  13. Sempau L, Martín-Sáez E, Gutiérrez-Rodríguez C, Gutiérrez-Ortega MC. Urticaria multiforme: a report of 5 cases and a review of the literature. Actas Dermosifiliogr. 2016;107(1):e1–5.

    Article  CAS  Google Scholar 

  14. Kotlyar S. Images In Clinical Medicine. Urticaria multiforme. N Engl J Med. 2016;375(5):470.

    Article  Google Scholar 

  15. •• Ercan N, Samorano LP, Fernandez VV, Valente NYS, Arnone M, Nico MMS, et al. Corticosteroid use in urticaria multiforme cases. Allergol Int. 2017;66(3):488–9 A response detailing the lack of clinical efficacy of corticosteroid treatment for UM.

    Article  Google Scholar 

  16. Siedner-Weintraub Y, Gross I, David A, Reif S, Molho-Pessach V. Paediatric erythema multiforme: epidemiological, clinical and laboratory characteristics. Acta Derm Venereol. 2017;97(4):489–92.

    Article  Google Scholar 

  17. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on erythema multiforme. Clin Rev Allergy Immunol. 2018;54(1):177–84.

    Article  CAS  Google Scholar 

  18. Read J, Keijzers GB. Pediatric erythema multiforme in the emergency department: more than “just a rash.”. Pediatr Emerg Care. 2017;33(5):320–4.

    Article  Google Scholar 

  19. Heinze A, Tollefson M, Holland KE, Chiu YE. Characteristics of pediatric recurrent erythema multiforme. Pediatr Dermatol. 2018;35(1):97–103.

    Article  Google Scholar 

  20. Coates SJ, Briggs B, Cordoro KM. Tularemia-induced erythema multiforme minor in an 11-year-old girl. Pediatr Dermatol. 2018;35(4):478–81.

    Article  Google Scholar 

  21. Chen T, Levitt J, Geller L. Apremilast for treatment of recurrent erythema multiforme. Dermatol Online J. 2017;23(1).

  22. Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017;76(5):811–817.e4.

    Article  Google Scholar 

  23. Basu S, Shanbhag SS, Gokani A, Kedar R, Bahuguna C, Sangwan VS. Chronic ocular sequelae of Stevens-Johnson syndrome in children: long-term impact of appropriate therapy on natural history of disease. Am J Ophthalmol. 2018;189:17–28.

    Article  Google Scholar 

  24. Schneider JA, Cohen PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther. 2017;34(6):1235–44.

    Article  CAS  Google Scholar 

  25. Antoon JW, Goldman JL, Lee B, Schwartz A. Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatr Dermatol. 2018;35(2):182–7.

    Article  Google Scholar 

  26. Manolio Teri A, Hutter Carolyn M, Mark A, Ricardo C, Davis Robert L, Denny Joshua C, et al. Research directions in genetic predispositions to Stevens–Johnson syndrome/toxic epidermal necrolysis. Clin Pharmacol Ther. 2018;103(3):390–4.

    Article  CAS  Google Scholar 

  27. White ML, Chodosh J, Jang J, Dohlman C. Incidence of Stevens-Johnson syndrome and chemical burns to the eye. Cornea. 2015;34(12):1527–33.

    Article  Google Scholar 

  28. Conner CD, McKenzie E, Owen CE, Callen JP. The use of cyclosporine for Stevens-Johnson syndrome-toxic epidermal necrolysis spectrum at the University of Louisville: a case series and literature review. Dermatol Online J. 2018;24(1).

  29. Sorrell J, Anthony L, Rademaker A, Belknap SM, Callahan S, West DP, et al. Score of toxic epidermal necrosis predicts the outcomes of pediatric epidermal necrolysis. Pediatr Dermatol. 2017;34(4):433–7.

    Article  Google Scholar 

  30. Beck A, Quirke KP, Gamelli RL, Mosier MJ. Pediatric toxic epidermal necrolysis: using SCORTEN and predictive models to predict morbidity when a focus on mortality is not enough. J Burn Care Res Off Publ Am Burn Assoc. 2015;36(1):167–77.

    Article  Google Scholar 

  31. Ferrándiz-Pulido C, García-Fernández D, Domínguez-Sampedro P, García-Patos V. Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a University Hospital. J Eur Acad Dermatol Venereol. 2011;25(10):1153–9.

    Article  Google Scholar 

  32. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387–97.

    Article  CAS  Google Scholar 

  33. •• Wang C-W, Yang L-Y, Chen C-B, Ho H-C, Hung S-I, Yang C-H, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985–96 A randomized control trial studying the efficacy of etanercept in adult SJS/TEN found improved clinical outcomes with etanercept compared to treatment with corticosteroids, an improvement in SCORTEN-predicted mortality, as well as reductions in TNF-α and granulysin secretions in patient plasma and blister fluids.

    Article  Google Scholar 

  34. Lerch M, Mainetti C, Beretta-Piccoli BT, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147–76.

    Article  CAS  Google Scholar 

  35. Chahal D, Aleshin M, Turegano M, Chiu M, Worswick S. Vaccine-induced toxic epidermal necrolysis: a case and systematic review. Dermatol Online J. 2018;24(1).

  36. • Lee HY, Fook-Chong S, Koh HY, Thirumoorthy T, Pang SM. Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol. 2017;76(1):106–13 A retrospective cohort study of 44 adult SJS/TEN patients evaluating efficacy of cyclosporine treatment found improvements in SCORTEN-predicted mortality with use of cyclosporine.

    Article  CAS  Google Scholar 

  37. St. John J, Ratushny V, Liu KJ, Bach DQ, Badri O, Gracey LE, et al. Successful use of cyclosporin A for Stevens-Johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol. 2017;34(5):540–6.

    Article  Google Scholar 

  38. Han F, Zhang J, Guo Q, Feng Y, Gao Y, Guo L, et al. Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. J Crit Care. 2017;42:65–8.

    Article  Google Scholar 

  39. Bellodi-Schmidt F, Shah KN. Beyond psoriasis: novel uses for biologic response modifiers in pediatric dermatology. Pediatr Dermatol. 2016;33(1):18–27.

    Article  Google Scholar 

  40. Woolridge KF, Boler PL, Lee BD. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis. Cutis. 2018;101(1):E15–21.

    PubMed  Google Scholar 

  41. Gavigan GM, Kanigsberg ND, Ramien ML. Pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis halted by Etanercept. J Cutan Med Surg. 2018;1:1203475418758989.

    Google Scholar 

  42. Narita YM, Hirahara K, Mizukawa Y, Kano Y, Shiohara T. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol. 2011;38(3):236–45.

    Article  Google Scholar 

  43. Hung P-C, Wang H-S, Hsia S-H, Wong AM-C. Plasmapheresis as adjuvant therapy in Stevens–Johnson syndrome and hepatic encephalopathy. Brain and Development. 2014;36(4):356–8.

    Article  Google Scholar 

  44. Hinc-Kasprzyk J, Polak-Krzemińska A, Głowacka M, Ożóg-Zabolska I. The use of plasmapheresis in a 4-year-old boy with toxic epidermal necrosis. Anaesthesiol Intensive Ther. 2015;47(3):210–3.

    Article  Google Scholar 

  45. • Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol. 2017;177(4):924–35 A review evaluating long-term complications of SJS/TEN that highlights the multi-organ involvement of the disease, with respect to chronic, delayed sequelae that occur in survivors. In particular, this review describes pulmonary, urogenital, gastrointestinal, and psychological sequelae, and provides an assessment protocol to be used during follow-up in the chronic stage of disease.

    Article  CAS  Google Scholar 

  46. Catt CJ, Hamilton GM, Fish J, Mireskandari K, Ali A. Ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Am J Ophthalmol. 2016;166:68–75.

    Article  Google Scholar 

  47. Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, et al. Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol. 2015;160(2):228–237.e2.

    Article  Google Scholar 

  48. Kohanim S, Palioura S, Saeed HN, Akpek EK, Amescua G, Basu S, et al. Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis - a comprehensive review and guide to therapy. II Ophthalmic Disease Ocul Surf. 2016;14(2):168–88.

    Article  Google Scholar 

  49. Rathi VM, Taneja M, Dumpati S, Mandathara PS, Sangwan VS. Role of scleral contact lenses in management of coexisting keratoconus and Stevens-Johnson Syndrome. Cornea. 2017;36(10):1267–9.

    PubMed  Google Scholar 

  50. Sharma N, Thenarasun SA, Kaur M, Pushker N, Khanna N, Agarwal T, et al. Adjuvant role of amniotic membrane transplantation in acute ocular Stevens–Johnson syndrome: a randomized control trial. Ophthalmology. 2016;123(3):484–91.

    Article  Google Scholar 

  51. Ahmad MS, Frank GS, Hink EM, Palestine AG, Gregory DG, McCourt EA. Amniotic membrane transplants in the pediatric population. J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus. 2017;21(3):215–8.

    Article  Google Scholar 

  52. Yoon HJ, Kim MK, Seo KY, Ueta M, Yoon KC. Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens–Johnson syndrome. Int Ophthalmol. 2017;18:1–8.

    Google Scholar 

  53. Chang J-H, Garg NK, Lunde E, Han K-Y, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57(5):415–29.

    Article  Google Scholar 

  54. Kim RY, Chung SK, Kim MS, Ra H. Effects of combined photodynamic therapy and topical bevacizumab treatment on corneal neovascularization in rabbits. Cornea. 2016;35(12):1615–20.

    Article  Google Scholar 

  55. Meneux E, Wolkenstein P, Haddad B, Roujeau JC, Revuz J, Paniel BJ. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol. 1998;91(2):283–7.

    Article  CAS  Google Scholar 

  56. Saeed H, Mantagos IS, Chodosh J. Complications of Stevens–Johnson syndrome beyond the eye and skin. Burns. 2016;42(1):20–7.

    Article  Google Scholar 

  57. Van Batavia JP, Chu DI, Long CJ, Jen M, Canning DA, Weiss DA. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Pediatr Urol. 2017;13(5):490.e1–7.

    Article  Google Scholar 

  58. Petukhova TA, Maverakis E, Ho B, Sharon VR. Urogynecologic complications in Stevens-Johnson syndrome and toxic epidermal necrolysis: presentation of a case and recommendations for management. JAAD Case Rep. 2016;2(3):202–5.

    Article  Google Scholar 

  59. Koh MJ-A, Tay Y-K. Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children. J Am Acad Dermatol. 2010;62(1):54–60.

    Article  CAS  Google Scholar 

  60. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Drug Saf. 2002;25(13):965–72.

    Article  Google Scholar 

Download references

Funding

EBH is supported by the Society of Pediatric Dermatology’s Weston Career Development Award and the Dermatology Foundation’s Pediatric Dermatology Career Development Award.

Author information

Authors and Affiliations

  1. Boston University School of Medicine, Boston, MA, USA

    Priya Cherukuri

  2. Department of Medicine, Boston, Brigham & Women’s Hospital, Boston, MA, USA

    Diana W. Bartenstein

  3. Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, 50 Staniford Street Suite 200, Boston, MA, 02114, USA

    Elena B. Hawryluk

Authors
  1. Priya Cherukuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana W. Bartenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elena B. Hawryluk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elena B. Hawryluk.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

EBH is an author/contributor at UpToDate, Inc.; EBH spouse employment and stock at Gritstone Oncology, Inc.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hospital-based Dermatology

This work was not previously presented.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cherukuri, P., Bartenstein, D.W. & Hawryluk, E.B. Pediatric Inpatient Dermatology: New Insights on Severe Eruptions and Cutaneous Adverse Reactions. Curr Derm Rep 7, 239–248 (2018). https://doi.org/10.1007/s13671-018-0242-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-018-0242-9

Keywords

Search

Navigation